 This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor TNF monoclonal antibody adalimumab ADA in patients with moderately to severely active ulcerative colitis UC. 